论文部分内容阅读
由非粘液性卵巢癌产生的CA125抗原决定簇已应用为卵巢癌病人的肿瘤标志物。可与鼠的单克隆抗体OC125起内反应而决定其同一性。在明显的上皮性卵巢癌患者中有90%CA125升高、并随肿瘤的发展或消退血清CA125而升降。有些子宫颈或子宫内膜腺癌患者也可见血清CA125升高,故认为CA125是一种演变抗原,是由胎儿的及成人的体腔上皮衍生物产生,由卵巢上皮肿癌细胞再表述。
The CA125 epitope produced by non-mucinous ovarian cancer has been used as a tumor marker for ovarian cancer patients. It can react with the murine monoclonal antibody OC125 to determine its identity. In patients with overt epithelial ovarian cancer, 90% of CA125 is elevated and rises and falls with the development of the tumor or the regression of serum CA125. Some patients with cervical or endometrial adenocarcinoma also showed elevated serum CA125, so that CA125 is an evolved antigen, is derived from the fetal and adult body cavity epithelial derivatives, re-described by epithelial ovarian cancer cells.